Regeneron Pharmaceuticals
Patents, Design & Utilities
Last updated:
List of all Regeneron Pharmaceuticals patents 238 in total
| Status | Patent |
|---|---|
Application | Utility: METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA Filling date: 5 Sep 2025 Issue date: 10 Mar 2022 |
Application | Utility: PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF Filling date: 5 Sep 2025 Issue date: 10 Mar 2022 |
Grant | Utility: CHO integration sites and uses thereof Filling date: 5 Sep 2025 Issue date: 8 Mar 2022 |
Grant | Utility: Anti-IL36R antibodies Filling date: 5 Sep 2025 Issue date: 8 Mar 2022 |
Application | Utility: METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR Filling date: 5 Sep 2025 Issue date: 3 Mar 2022 |
Grant | Utility: Restricted immunoglobulin heavy chain mice Filling date: 5 Sep 2025 Issue date: 1 Mar 2022 |
Grant | Utility: Humanized T cell mediated immune responses in non-human animals Filling date: 5 Sep 2025 Issue date: 1 Mar 2022 |
Application | Utility: PERFUSION BIOREACTOR AND RELATED METHODS OF USE Filling date: 5 Sep 2025 Issue date: 24 Feb 2022 |
Application | Utility: Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists Filling date: 5 Sep 2025 Issue date: 24 Feb 2022 |
Application | Utility: Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy Filling date: 5 Sep 2025 Issue date: 24 Feb 2022 |
Grant | Utility: Use of a VEGF antagonist to treat angiogenic eye disorders Filling date: 5 Sep 2025 Issue date: 22 Feb 2022 |
Grant | Utility: Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies Filling date: 5 Sep 2025 Issue date: 22 Feb 2022 |
Application | Utility: Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) Filling date: 5 Sep 2025 Issue date: 17 Feb 2022 |
Grant | Utility: System and method of analysis of a protein using liquid chromatography-mass spectrometry Filling date: 5 Sep 2025 Issue date: 15 Feb 2022 |
Application | Utility: METHODS OF TREATING OCULAR CANCER USING ANTI-MET ANTIBODIES AND BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET Filling date: 5 Sep 2025 Issue date: 10 Feb 2022 |
Grant | Utility: Room temperature stable lyophilized protein Filling date: 5 Sep 2025 Issue date: 8 Feb 2022 |
Application | Utility: NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX Filling date: 5 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: Stabilized Formulations Containing Anti-CTLA-4 Antibodies Filling date: 5 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: Sustained Release Formulations Using Non-Aqueous Emulsions Filling date: 5 Sep 2025 Issue date: 13 Jan 2022 |
Application | Utility: Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules That Bind PSMA and CD3, and Uses Thereof Filling date: 5 Sep 2025 Issue date: 30 Dec 2021 |
Application | Utility: Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies Filling date: 5 Sep 2025 Issue date: 30 Dec 2021 |
Application | Utility: APLNR Modulators and Uses Thereof Filling date: 5 Sep 2025 Issue date: 30 Dec 2021 |
Application | Utility: NY-ESO-1 T CELL RECEPTORS AND METHODS OF USE THEREOF Filling date: 5 Sep 2025 Issue date: 30 Dec 2021 |
Application | Utility: CAS-READY MOUSE EMBRYONIC STEM CELLS AND MICE AND USES THEREOF Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: HEAVY PEPTIDE APPROACH TO ACCURATELY MEASURE UNPROCESSED C-TERMINAL LYSINE Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: ACTIVIN A ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: Methods for Treating or Preventing SARS-CoV-2 Infections and COVID-19 with Anti-SARS-CoV-2 Spike Glycoprotein Antibodies Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: VEGF Antagonist Formulations Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: VEGF Antagonist Formulations Filling date: 5 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN Filling date: 5 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN Filling date: 5 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: INTRALESIONAL ADMINISTRATION OF PD-1 INHIBITORS FOR TREATING SKIN CANCER Filling date: 5 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: HUMAN ANTIBODIES TO PD-L1 Filling date: 5 Sep 2025 Issue date: 9 Dec 2021 |
Application | Utility: HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES Filling date: 5 Sep 2025 Issue date: 9 Dec 2021 |
Application | Utility: METHOD AND CHROMATOGRAPHY SYSTEM FOR DETERMINING AMOUNT AND PURITY OF A MULTIMERIC PROTEIN Filling date: 5 Sep 2025 Issue date: 9 Dec 2021 |
Application | Utility: 17 -Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof Filling date: 5 Sep 2025 Issue date: 9 Dec 2021 |
Grant | Utility: Perfusion bioreactor and related methods of use Filling date: 5 Sep 2025 Issue date: 7 Dec 2021 |
Application | Utility: HUMANIZED IL-4 AND IL-4Ra ANIMALS Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: METHODS AND COMPOSITIONS COMPRISING REDUCED LEVEL OF HOST CELL PROTEINS Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: GAIT ANALYSIS SYSTEM Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: Genetically Modified Non-Human Animals And Methods Of Use Thereof Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses Thereof Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ Filling date: 5 Sep 2025 Issue date: 2 Dec 2021 |
Grant | Utility: Anti-VEGF protein compositions and methods for producing the same Filling date: 5 Sep 2025 Issue date: 30 Nov 2021 |
Grant | Utility: Method of characterization of visible and/or sub-visible particles in biologics Filling date: 5 Sep 2025 Issue date: 30 Nov 2021 |
Application | Utility: Anti-IL-33 Antibodies and Uses Thereof Filling date: 5 Sep 2025 Issue date: 25 Nov 2021 |
Application | Utility: NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 Filling date: 5 Sep 2025 Issue date: 25 Nov 2021 |
Grant | Utility: 17.beta.-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof Filling date: 5 Sep 2025 Issue date: 23 Nov 2021 |
Showing 100 to 150 of 238 patents.